Cargando…
Oncogenic LINC00857 recruits TFAP2C to elevate FAT1 expression in gastric cancer
FAT atypical cadherin 1 (FAT1) is a mutant gene frequently found in human cancers and mainly accumulates at the plasma membrane of cancer cells. Emerging evidence has implicated FAT1 in the progression of gastric cancer (GC). This study intended to identify a regulatory network related to FAT1 in GC...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807510/ https://www.ncbi.nlm.nih.gov/pubmed/35524544 http://dx.doi.org/10.1111/cas.15394 |
_version_ | 1784862735208546304 |
---|---|
author | Zhang, Wenqing Ji, Kaiyue Min, Congcong Zhang, Cuiping Yang, Lin Zhang, Qi Tian, Zibin Zhang, Mengyuan Wang, Xinyu Li, Xiaoyu |
author_facet | Zhang, Wenqing Ji, Kaiyue Min, Congcong Zhang, Cuiping Yang, Lin Zhang, Qi Tian, Zibin Zhang, Mengyuan Wang, Xinyu Li, Xiaoyu |
author_sort | Zhang, Wenqing |
collection | PubMed |
description | FAT atypical cadherin 1 (FAT1) is a mutant gene frequently found in human cancers and mainly accumulates at the plasma membrane of cancer cells. Emerging evidence has implicated FAT1 in the progression of gastric cancer (GC). This study intended to identify a regulatory network related to FAT1 in GC development. Upregulated expression of FAT1 was confirmed in GC tissues, and silencing FAT1 was observed to result in suppression of GC cell oncogenic phenotypes. Mechanistic investigation results demonstrated that FAT1 upregulated AP‐1 expression by phosphorylating c‐JUN and c‐FOS, whereas LINC00857 elevated the expression of FAT1 by recruiting a transcription factor TFAP2C. Functional experiments further suggested that LINC00857 enhanced the malignant biological characteristics of GC cells through TFAP2C‐mediated promotion of FAT1. More importantly, LINC00857 silencing delayed the tumor growth and blocked epithelial–mesenchymal transition in tumor‐bearing mice, which was associated with downregulated expression of TFAP2C/FAT1. To conclude, LINC00857 plays an oncogenic role in GC through regulating the TFAP2C/FAT1/AP‐1 axis. Therefore, this study contributes to extended the understanding of gastric carcinogenesis and LINC00857 may serve as a therapeutic target for GC. |
format | Online Article Text |
id | pubmed-9807510 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98075102023-01-04 Oncogenic LINC00857 recruits TFAP2C to elevate FAT1 expression in gastric cancer Zhang, Wenqing Ji, Kaiyue Min, Congcong Zhang, Cuiping Yang, Lin Zhang, Qi Tian, Zibin Zhang, Mengyuan Wang, Xinyu Li, Xiaoyu Cancer Sci Original Articles FAT atypical cadherin 1 (FAT1) is a mutant gene frequently found in human cancers and mainly accumulates at the plasma membrane of cancer cells. Emerging evidence has implicated FAT1 in the progression of gastric cancer (GC). This study intended to identify a regulatory network related to FAT1 in GC development. Upregulated expression of FAT1 was confirmed in GC tissues, and silencing FAT1 was observed to result in suppression of GC cell oncogenic phenotypes. Mechanistic investigation results demonstrated that FAT1 upregulated AP‐1 expression by phosphorylating c‐JUN and c‐FOS, whereas LINC00857 elevated the expression of FAT1 by recruiting a transcription factor TFAP2C. Functional experiments further suggested that LINC00857 enhanced the malignant biological characteristics of GC cells through TFAP2C‐mediated promotion of FAT1. More importantly, LINC00857 silencing delayed the tumor growth and blocked epithelial–mesenchymal transition in tumor‐bearing mice, which was associated with downregulated expression of TFAP2C/FAT1. To conclude, LINC00857 plays an oncogenic role in GC through regulating the TFAP2C/FAT1/AP‐1 axis. Therefore, this study contributes to extended the understanding of gastric carcinogenesis and LINC00857 may serve as a therapeutic target for GC. John Wiley and Sons Inc. 2022-11-08 /pmc/articles/PMC9807510/ /pubmed/35524544 http://dx.doi.org/10.1111/cas.15394 Text en © 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Zhang, Wenqing Ji, Kaiyue Min, Congcong Zhang, Cuiping Yang, Lin Zhang, Qi Tian, Zibin Zhang, Mengyuan Wang, Xinyu Li, Xiaoyu Oncogenic LINC00857 recruits TFAP2C to elevate FAT1 expression in gastric cancer |
title | Oncogenic LINC00857 recruits TFAP2C to elevate FAT1 expression in gastric cancer |
title_full | Oncogenic LINC00857 recruits TFAP2C to elevate FAT1 expression in gastric cancer |
title_fullStr | Oncogenic LINC00857 recruits TFAP2C to elevate FAT1 expression in gastric cancer |
title_full_unstemmed | Oncogenic LINC00857 recruits TFAP2C to elevate FAT1 expression in gastric cancer |
title_short | Oncogenic LINC00857 recruits TFAP2C to elevate FAT1 expression in gastric cancer |
title_sort | oncogenic linc00857 recruits tfap2c to elevate fat1 expression in gastric cancer |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807510/ https://www.ncbi.nlm.nih.gov/pubmed/35524544 http://dx.doi.org/10.1111/cas.15394 |
work_keys_str_mv | AT zhangwenqing oncogeniclinc00857recruitstfap2ctoelevatefat1expressioningastriccancer AT jikaiyue oncogeniclinc00857recruitstfap2ctoelevatefat1expressioningastriccancer AT mincongcong oncogeniclinc00857recruitstfap2ctoelevatefat1expressioningastriccancer AT zhangcuiping oncogeniclinc00857recruitstfap2ctoelevatefat1expressioningastriccancer AT yanglin oncogeniclinc00857recruitstfap2ctoelevatefat1expressioningastriccancer AT zhangqi oncogeniclinc00857recruitstfap2ctoelevatefat1expressioningastriccancer AT tianzibin oncogeniclinc00857recruitstfap2ctoelevatefat1expressioningastriccancer AT zhangmengyuan oncogeniclinc00857recruitstfap2ctoelevatefat1expressioningastriccancer AT wangxinyu oncogeniclinc00857recruitstfap2ctoelevatefat1expressioningastriccancer AT lixiaoyu oncogeniclinc00857recruitstfap2ctoelevatefat1expressioningastriccancer |